Esperion Therapeutics Confirms Acquisition by Essence Parent for $3.16/Share Plus CVRs, Details Corstasis Acquisition and Q1 Financials

summarizeSummary

Esperion Therapeutics confirms its acquisition by Essence Parent for $3.16/share cash plus CVRs, details the recent Corstasis acquisition, and reports Q1 2026 financials showing revenue growth but an unremediated material weakness in internal controls.

check_boxKey Events

• Definitive Merger Agreement Confirmed

  Esperion Therapeutics entered into a definitive agreement on May 1, 2026, to be acquired by Essence Parent Inc. for $3.16 per share in cash, plus one contractual contingent value right (CVR) per share, representing the right to participate in contingent payments of up to an additional $100 million upon achievement of certain milestones. The merger is expected to close in Q3 2026.

• Corstasis Therapeutics Acquisition Completed

  On April 2, 2026, Esperion completed the acquisition of Corstasis Therapeutics Inc. for an aggregate upfront consideration of $75 million in cash, with potential milestone payments up to $180 million. This acquisition expands Esperion's cardiovascular portfolio with Enbumyst (bumetanide nasal spray).

• New Financing Secured for Acquisition

  To finance the Corstasis acquisition, Esperion secured an additional $25 million term loan and entered into a $50 million royalty purchase agreement related to royalties from the Otsuka Territory, both on April 2, 2026.

• Q1 2026 Financial Performance

  Total revenues for Q1 2026 increased to $80.1 million from $65.0 million in Q1 2025. The net loss decreased to $25.2 million in Q1 2026 from $40.5 million in Q1 2025. However, net cash used in operating activities increased to $27.7 million from $22.6 million in the prior year period.

auto_awesomeAnalysis

This 10-Q filing provides comprehensive financial and operational updates, most notably confirming the definitive merger agreement with Essence Parent Inc. for $3.16 per share in cash plus contingent value rights (CVRs) up to an additional $100 million. This acquisition, previously announced on May 1, 2026, represents a significant event for shareholders, offering a premium to the current stock price. Additionally, the filing details the completed acquisition of Corstasis Therapeutics Inc. on April 2, 2026, for $75 million upfront cash and up to $180 million in milestones, expanding Esperion's cardiovascular portfolio. While Q1 2026 financial results show increased revenue and a reduced net loss, the company reported an increased net cash outflow from operating activities and an unremediated material weakness in internal control over financial reporting, which remains a concern for investors. The ongoing ANDA litigation also presents a continuing risk, though some settlements have been reached.